Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA® and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has ...

Journal Reference: Reichel et al. SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Testing and Analysis, 2009 DOI: 10.1002/dta.97 ...

Patients in the study were on in-center hemodialysis for more than 6 months between June 1, 2023, and July 15, 2023, and had been receiving MPG-EPO at high doses (defined as 100 g/dose or higher ...

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera April 11, 2023 04:28 AM Eastern ...

Switzerland’s Roche has suffered a dent to its stock after revealing that it has temporarily suspended recruitment into a Phase II dose-finding study with its new anaemia drug Mircera. The company ...

Pasche also sees other potential negatives for Amgen's beleaguered EPO franchise looming in the future, including the biotech company losing its patent challenge against Mircera.

Patent Watch Published: November 2008 Patent watch Charlotte Harrison Nature Reviews Drug Discovery 7, 882–883 (2008) Cite this article ...

Amgen has won another round in its legal battle in the USA to protect its anaemia drugs Aranesp and Epogen and prevent Roche from launching its rival product Mircera. The US District Court in Boston ...

The Swiss company has a definite interest in entering the market with its Mircera product. Amgen’s two drugs, Aranesp and Epogen, generated alone sales in 2006 of nearly $7 billion (SFr8.22 ...

CERA is the latest form of EPO, and is similar to the previous drugs, except that it is connected to a chemical called polyethylene glycol (PEG), which makes it last longer in the body.